Recruiting
Phase 2

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05007873

Conditions

Chronic Phase Chronic Myelogenous Leukemia

Philadelphia Chromosome Positive

BCR-ABL1 Positive Chronic Myelogenous Leukemia

BCR-ABL1 Positive

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dasatinib

Decitabine and Cedazuridine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information